Gilde Healthcare’s private equity fund today announced the acquisition of MEG Medical Equipment GmbH (“MEG”), a provider of high-quality medical aids for treatment and prevention of decubitus and other skin...
Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake...
October 15, 2025
Gilde Healthcare acquires MEG, a group of specialized providers of medical aids, from Harald Quandt Industriebeteiligungen (“HQIB”)
Gilde Healthcare’s private equity fund today announced the acquisition of MEG Medical Equipment GmbH (“MEG”), a provider of high-quality medical aids for treatment and prevention of decubitus and other skin...
November 14, 2025
Gilde Healthcare acquires MEG, a group of specialized providers of medical aids, from Harald Quandt Industriebeteiligungen (“HQIB”)
Gilde Healthcare’s private equity fund today announced the acquisition of MEG Medical Equipment GmbH (“MEG”), a provider of high-quality medical aids for treatment and prevention of decubitus and other skin...
November 14, 2025
Filter & search
Fund strategy:
Loading...
These were all articles
44c5b029f2